SOURCE: The Wall Street Analyzer

client upload did not work

August 19, 2015 11:10 ET

At the Forefront of Immunology: WSA Interviews Immune Pharma and TapImmune

Wall Street Analyzer's CEO Interview Series

NEW YORK, NY--(Marketwired - August 19, 2015) - Immune Pharmaceuticals Inc. (NASDAQ: IMNP) CEO Dr. Daniel Teper took time to update investors on the company's recent license agreement for AmiKet Nano as well as initiation of two Phase II clinical studies with bertilimumab, their lead monoclonal antibody. The first study targets ulcerative colitis and the second study is in bullous pemphigoid which is an autoimmune skin disease. In addition, Dr. Teper discussed some of the other indications and possible applications for bertilimumab and talked about IMNP's seasoned management team. He stated that the company expects further clinical data in the next six to eighteen months.


TapImmune Inc. (OTCQB: TPIV) CEO Dr. Glynn Wilson discussed the company's Phase I trial for the vaccine TPIV100, which showed positive immune response data in 19 of 20 HER2/neu breast cancer patients. This comes on the heels of a successful Phase I trial of a folate receptor alpha vaccine, TPIV200, for ovarian and triple negative breast cancer. Dr. Wilson touched on TPIV's licensing agreement with Mayo Clinic for TPIV200 and went over the structure of the company's new financing. He also discussed recent additions to TapImmune's board of directors and spoke on key trends in immunotherapy in relation to the company.



PEDEVCO (NYSE: PED) Announces 2nd Quarter and Six Month results.


About WSA:

The Wall Street Analyzer's aim is to provide investors with the tools they need to make informed decisions on holding stocks. Our staff includes a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum. On one hand, our financial experience gives us the ability to identify promising, off the grid companies before the rest of the market uncovers them, and on the other, our media experience allows us to produce interviews which appeal to a larger audience. Our philosophy is to turn ticker symbols into engaging stories and technical data into entertaining content. Visit:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as SLWF or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, such statements in this release that describe the company's business strategy, outlook, objectives, plans, intentions, or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. These risks and uncertainties include, among other things, product price volatility, product demand, market competition, and risk inherent in the operations of a company. We assume no obligation to update any written or oral forward-looking statement made by us or on our behalf as a result of new information, future events or other factors.

Contact Information


    Immune Pharmaceuticals:
    Christine Petraglia
    Director of Investor Relations
    Email contact

    TAPImmune, Inc:
    Kirin M. Smith
    PCG Advisory
    Email contact

    Bonnie Tang
    Pacific Energy Development
    1-855-733-3826 ext. 21 (Media)
    Email contact